XBiotech (XBIT) Operating Expenses (2014 - 2026)
XBiotech (XBIT) posted quarterly Operating Expenses of $29.8 million for Q4 2025, up 240.13% year-over-year from $8.7 million in Q4 2024, and up 392.06% quarter-over-quarter from $6.0 million in Q3 2025.
XBiotech (XBIT) Operating Expenses (2014 - 2026) Analysis & Trends
XBiotech's Operating Expenses history runs 12 years deep, the most recent figure standing at $29.8 million for Q4 2025.
- In Q4 2025, Operating Expenses rose 240.13% year-over-year to $29.8 million; the TTM figure through Dec 2025 stood at $55.7 million (up 31.12% YoY), while the FY2025 annual figure was $55.7 million, up 31.11% from the prior year.
- Operating Expenses for Q4 2025 stood at $29.8 million, up from $6.0 million in the prior quarter.
- The five-year high for Operating Expenses was $29.8 million in Q4 2025, with the low at $6.0 million in Q3 2025.
- The 5-year median for Operating Expenses is $8.6 million (2023), against an average of $10.6 million.
- Peak annual rise in Operating Expenses reached 240.13% in 2025, while the deepest fall reached 57.66% in 2025.
- XBiotech's Operating Expenses stood at $10.6 million in 2021, then declined by 20.68% to $8.4 million in 2022, then climbed by 1.67% to $8.6 million in 2023, then rose by 1.87% to $8.7 million in 2024, then surged by 240.13% to $29.8 million in 2025.
- Business Quant data shows XBIT's Operating Expenses at $29.8 million in Q4 2025, $6.0 million in Q3 2025, and $6.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | XBiotech | 68.90 Mn | 68.90 Mn | - | 6.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.15 Mn |
| Dec 31, 2025 | 29.76 Mn |
| Sep 30, 2025 | 6.05 Mn |
| Jun 30, 2025 | 6.34 Mn |
| Mar 31, 2025 | 13.55 Mn |
| Dec 31, 2024 | 8.75 Mn |
| Sep 30, 2024 | 7.90 Mn |
| Jun 30, 2024 | 14.97 Mn |
| Mar 31, 2024 | 10.85 Mn |
| Dec 31, 2023 | 8.59 Mn |
| Sep 30, 2023 | 8.52 Mn |
| Jun 30, 2023 | 13.26 Mn |
| Mar 31, 2023 | 7.15 Mn |
| Dec 31, 2022 | 8.45 Mn |
| Sep 30, 2022 | 7.85 Mn |
| Jun 30, 2022 | 13.42 Mn |
| Mar 31, 2022 | 8.13 Mn |
| Dec 31, 2021 | 10.65 Mn |
| Sep 30, 2021 | 7.14 Mn |
| Jun 30, 2021 | 13.77 Mn |